The Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market would witness Market growth of 10.7% CAGR during the forecast period (2022-2028).
Preimplantation genetic testing is increasingly being utilized by healthcare practitioners and institutions to identify problems present in embryos before implantation, as it has been shown to be an effective approach for diagnosing genetic disorders. Thus, in the next years, the demand for preimplantation genetic testing will be fueled by the need for better diagnostic methods to combat the increased prevalence of genetic diseases in babies.
Because of the rising number of cases with genetically imbalanced structures observed in children and neonates, preimplantation genetic diagnosis is considered a critical process. Preimplantation genetic diagnosis entails examining an embryo for a specific genetic condition before it implants. PGD is used to ensure that embryos that are not affected by the condition can return to the uterus. The PGD allows researchers to examine the DNA of eggs or embryos in order to select those with specific mutations for hereditary illnesses. When there are early chromosomal or genetic problems in the family, as well as in the context of in vitro fertilization programs, preimplantation genetic diagnostics are useful.
Before a reproductive clinic in Western Australia can generate embryos for PGD, it must first get authorisation from the WA Reproductive Technology Council (Council). This is to ensure that embryo testing is only done when there is a significant chance of a serious genetic problem (rather than for other reasons such as sex selection of embryos, which is illegal in Australia) and that patients have received proper genetic counseling. The Council examines the danger and severity of the condition, the test's safety and reliability, and the condition's impact on both the prospective child and the family before reaching a decision about PGD.
Developing countries such as China and India are participating in a number of reproductive health improvements, which have been supported by the introduction of a number of supportive government legislations.
The China Market dominated the Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market by Country in 2021, and would continue to be a dominant Market till 2028; thereby, achieving a Market value of $12,387 Thousands by 2028. The Japan Market is poised to grow at a CAGR of 10.1% during (2022 - 2028). Additionally, The India Market would display a CAGR of 11.4% during (2022 - 2028).
Based on Test Type, the Market is segmented into Aneuploidy, Chromosomal Abnormalities, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Preimplantation Genetics Diagnosis (PGD) Market is Projected to reach USD 159.8 Million by 2028, at a CAGR of 9.7%
The Market research report covers the analysis of key stake holders of the Market . Key companies profiled in the report include Illumina, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, PacGenomics, CeGaT GmbH, and Laboratory Corporation of America Holdings.
By Test Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 